icon-    folder.gif   Conference Reports for NATAP  
 
  21st Conference on Retroviruses and
Opportunistic Infections
Boston, MA March 3 - 6, 2014
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and
Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV)
 
 
  CROI: On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14)
 
HCV Coverage at CROI - (03/10/14)
 
Reported by Jules Levin
CROI 2014 March 3-6
Boston, MA
 
WW Yeh,1 W Marshall,1 J Ma,1 E Mangin,1 X Huang,1 Y Zhu,1 S Langley,1 P Jumes,1 S Youngberg,2 JR Butterton1
1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2Celerion, Lincoln, NE, USA

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif

CROI10.gif